INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the 3 rd most common cause of cancerrelated mortality in the United States 1 . The multistep progression of PDAC can occur on the backdrop of non-cystic, microscopic precursor lesions known as pancreatic intraepithelial neoplasias (PanINs), or alternatively, through a cystic pathway that portends a distinct natural history 2 . Overall, pancreatic cysts are identified in greater than 2 % of the general patient population, rising to 10% amongst individuals above 70 years of age 3 . Many of the cystic lesions are essentially benign, and harbor no risk of progression to PDAC. In contrast, mucinsecreting cysts of the pancreas, specifically intraductal papillary mucinous neoplasms (IPMNs),
are bona fide precursor lesions of PDAC 3 . Patients with non-invasive IPMNs have a 5-year survival rate of 90-100 % upon surgical resection, which is reduced to about 50% for those with an invasive component 4 . Nonetheless, in contrast to PDAC that arises through the non-cystic (PanIN) pathway to invasive neoplasia, and which is nearly always fatal, cancers arising in the context of IPMNs demonstrate a more indolent course. Further, even within the universe of IPMNs, the vast majority does not progress to PDAC, although the biological basis for this favorable outcome has, thus far, remained elusive.
Progress in translational research on pancreatic cystic lesions has been hampered by lack of animal models that recapitulate the biology and genetic of the cognate human disease. In 2011, we performed a comprehensive next generation sequencing (NGS) assessment of IPMNs, and identified two recurrent driver alterations, oncogenic mutations of KRAS and GNAS
METHODS

Genetically engineered mice
All animal studies were carried out according to the MD Anderson Institutional Care and Use of Animals Committee (IACUC)-approved protocols. To model the co-expression of mutant
Kras and Gnas in the murine pancreatic epithelium, we used a previously described doxycycline (doxy)-inducible Gnas R201C model 13 . In this model, tissue-specific expression of Gnas R201C is regulated by crossing the mice to an appropriate Cre-driver (in this case, p48-Cre). This leads to removal of a lox-STOP-lox (LSL) cassette upstream of a reverse tetracycline transactivator (rtTA) and expression of rtTA in the pancreatic epithelium. In the presence of doxy, rtTA binds to the Tet operon (TetO) upstream of Gnas R201C leading to transgene expression in the pancreas 13, 14 . We generated compound heterozygous p48-Cre; LSL-Kras G12D ; Rosa26R-LSL-rtTA-TetOGnas R201C mice (Kras; Gnas mice) ( Figure 1A ). Doxycycline diet was fed at a dose of 0.0060 %.
The time course for supplementation is outlined in the Figure 1B . The confirmation of recombination of Kras G12D and transcription of Gnas R201C are shown in the pancreatic lysates in
Supplementary Figure 1A and B.
Histological evaluation of pancreas
To histologically evaluate the multistep progression of pre-invasive neoplasms, including mPanINs or murine IPMNs (mIPMNs), the grade of ductal lesions was evaluated in representative pancreatic sections of cohorts of Kras; Gnas mice, with or without doxycycline at the age of 18, 28, and more than 40 weeks, respectively ( Figure 1B) . Only the highest-grade lesion per pancreatic lobule was evaluated, using published criteria for low-grade or high-grade mPanIN and mIPMN [15] [16] [17] . An average of 171 total pancreatic lobules were counted from 3 independent animals for each group. The data were expressed as a percentage of the total counted pancreatic lobules. Cystic papillary lesions in our mouse model were defined as epithelium-lined cystic structures >500μm, and composed of papillary epithelial proliferations with fibrovascular cores and varying degrees of cellular atypia, which is a sine qua non of human IPMNs 15 . Cystic papillary structures in the representative pancreatic sections which met the definition were counted to assess the neoplastic nature of Kras; Gnas mice. In terms of invasive carcinomas, they were graded based on the most poorly differentiated component when multiple histopathlogical grades were observed.
Establishment of primary pancreatic ductal adenocarcinoma cell lines with doxycycline inducible mutant Gnas
R201C
Freshly isolated murine PDAC tissues were minced by sterile scalpel and washed with PBS containing 1% penicillin and streptomycin and re-suspended in RPMI with 10 % fetal bovine serum (FBS) and 1% penicillin and streptomycin, and seeded in 60 mm collagen coated dishes.
Five days after seeding of tumor pieces, residual tissue was removed and attached colonies comprised of murine PDAC cells were isolated using 150μl cloning cylinders (Sigma-Aldrich, St
Louis, MO) and expanded. For the purpose of this study, the two cell lines used in all of the experiments are designated as "LGKC-1" and "LGKC-2", respectively. Both cell lines were used at less than passage 10 to minimize passage-dependent artifacts 18 .
Gene expression analysis and reverse-transcription quantitative polymerase chain reaction
Total RNA extraction from cultured LGKC-1 and LGKC-2 cells, as described previously 19 .
Microarray analysis was performed with the Agilent Mouse GE 4x44k v2 Microarray Kit (Agilent, Santa Clara, CA) using mRNA from mPDAC cell lines established from primary PDAC in the Kras; Gnas mice. These cells express mutant Kras constitutively, while mutant
Gnas expression can be turned on or off by doxycycline administration, producing and isogenic system. To identify differentially enriched gene sets, the raw intensities were quantile normalized and the data were subjected into Gene set enrichment analysis (GSEA) software, v2.2.3 20, 21 .
Gene sets collection from oncogenic signatures gene sets (v5.2) were used in the analysis. For RT-qPCR protocol, see Supplemental Materials and Methods.
Colony formation and invasion assays
Anchorage-independent growth in soft agar was assessed as described previously 22 . Invasion assay was performed as described previously 19 .
Allograft model for assessing tumor growth rates and differentiation
For in vivo growth and differentiation assays, murine PDAC cells (with or without additional genetic modifications of mYap1 as described in the text) were suspended in 100μl of 50%
Matrigel/PBS mix and injected subcutaneously into the lower flanks of age-matched female NUDE mice (n=4 per group). Twenty four hours after injection, the mice were randomized to be fed normal diet or doxycycline diet (0.6%). Tumor volumes were measured every 3-4 days for 17 days and tumor weight was measured at the end of the experiment. Histological assessment was conducted for grade of tumor differentiation, and additional immunohistochemistry and western blot analyses on the explanted tumors were conducted, as described below. Immunohistochemstry on archival human IPMNs samples was performed as described previously 19 .
Immunofluorescence and Immunohistochemistry
Protein extraction and Western blotting
Protein extraction and western blotting were performed as described previously 19 . Additional details on methodology and assessment are provided in the Supplementary Materials and Methods.
Statistical analysis
All analyses were performed in triplicate or greater and the means obtained were used for independent t-tests. Statistical analyses were carried out using the Prism 6 statistical analysis program (GraphPad Software, La Jolla, CA). Asterisks denote statistical significance (nonsignificant or NS, P>0.05; *P<0.05; **P<0.01; and***P<0.001). All data are reported as mean ± standard error of the mean (s. e. m.). 
RESULTS
Expression of Gnas
R201C
, in comparison to those with mutant Kras G12D at both time points.
In addition, more papillary structures were observed in the pancreata of the mice at the later time point, suggesting co-expression of mutant Gnas R201C progressively enhances the IPMN-specific phenotype ( Figure 1D , E).
The distribution for grades of all exocrine pancreatic precursor lesions including acinar-ductal metaplasia (ADM), mPanIN, and murine IPMN (mIPMN) were also assessed to determine the effect of mutant Gnas R201C on multistep progression of Kras G12D -driven neoplasia ( Figure 1F ). weeks old mice, respectively, Figure 1F ). These results indicate that Gnas R201C co-expression accelerates formation of precursor lesions in the setting of mutant Kras G12D .
In spontaneously aged mice to 40 weeks and beyond, irrespective of the administration of doxy, virtually the entire pancreatic parenchyma was eventually replaced by ductal neoplastic lesions intermingled fibrotic areas due, in part to the constitutive expression of the mutant Kras Despite a greater prevalence of high-grade precursor lesions, however, there was no significant difference in the frequency of invasive carcinoma upon co-expression of Gnas
. While the median survival of doxy administered Kras; Gnas mice were significantly shorter than control mice without doxy ( Figure 1H ). Of note, however, 8 of 10 doxy administered Kras; Gnas mice without invasive carcinoma were euthanized due to abdominal distention caused by large cyst formation within the pancreas, suggesting that measuring median survival alone was a confounding factor for assessing natural history of these mice.
In a cohort of 35 Kras; Gnas mice that was monitored for progression to invasive carcinoma (17 with doxy, and 18 without doxy administration), five mice in the doxy arm (29%) and six mice in the control arm (33%) developed invasive neoplasms at a median interval of 43 weeks. For further mechanistic analysis, we established PDAC cell lines from primary tumors that developed in the pancreata of 2 independent Kras; Gnas mice at the age of 8 and 10 months, respectively, which we named Linker; Gnas; Kras; Cre-1 (LGKC-1) and LGKC-2 cell lines ( Figure 2C) . Both of these cell lines represent an isogenic system, which constitutively express Kras G12D , but Gnas R201C is only co-expressed upon addition of doxy in vitro. Therefore, these lines can serve as a conduit for elucidating how aberrant cAMP alters signaling pathways on the backdrop of constitutively active Ras. Indeed, in vitro assays confirmed that both LGKC-1 and
All of the invasive carcinomas developing in the doxy-induced
LGKC-2 lines significantly upregulated cAMP levels upon doxy administration (Figure 2D) , as well as phospho-Protein Kinase A (pPKA) substrates ( Figure 2E ).
We then assessed anchorage-independent growth and invasiveness of LGKC-1 and LGKC-2 lines with or without doxy administration. Rather unexpectedly, the number of colony in soft agar was significantly decreased in both LGKC-1 and LGKC-2 lines by the induced expression of Gnas
R201C
, with a more profound reduction of colony formation observed in the LGKC-2 line ( Figure 3A) . On the same lines, invasive capacity of both lines was also attenuated in an in vitro Matrigel assays, upon Gnas R201C induction ( Figure 3B ). Mirroring the paradoxical in vitro data, subcutaneous allografts established from both LGKC-1 and LGKC-2 lines in doxy-fed athymic mice demonstrated reduced tumor weights compared to control allografted mice ( Figure 3C) Figure 3D ). This effect of mutant Gnas R201C on PDAC differentiation seems to be consistent with the findings in autochthonous
Kras; Gnas mice. The epithelial differentiation induced by Gnas R201C was more prominent in
LGKC-1 line, compared to LGKC-2, but this was not surprising given that the isogenic LGKC-2 allografts without doxy were essentially undifferentiated. Figure 3A) , suggesting that cAMP signaling might be suppressing this critical transcriptional co-activator implicated in PDAC pathogenesis.
Co-expression of Gnas
Indeed, in both LGKC-1 and LGKC-2 cells, activation of Gnas R201C signaling was associated with significant reduction in credentialed YAP1 target genes (mCtgf, mCyr61, mThbs1, mItgb5), albeit the effects were more striking in LGKC-2 cells (Supplementary Figure 3B) . As a transcriptional co-activator, activated YAP1 is localized in the nucleus, while cytoplasmic sequestration is indicative of phosphorylation and inactivation by the upstream Hippo kinase cascade. Indeed, upon Gnas R201C activation, YAP1 was substantially sequestered in the cytoplasm in both LGKC-1 and LGKC-2 cells (Figures 4A-B) , consistent with inactivation.
Assessment of nuclear and cytoplasmic extracts also confirmed evidence for cytoplasmic sequestration upon Gnas R201C activation ( Figure 4C) , with no changes in the levels of the main YAP1 binding partner and transcription factor Tead2. In LGKC-1 and LGKC-2 cells, doxycycline induction led to time-dependent phosphorylation of the immediate upstream kinase Lats1, which in turn, phosphorylates and inactivates YAP1 at two distinct serine residues (S127 and S397) ( Figure 4D ). The impact of doxycycline induction on YAP1 activation status in both
LGKC lines was pheno-copied by the cAMP elevator forskolin (Figure 4E ), which further reiterated that the effects were through the canonical signal transduction pathway downstream of Gαs. Orthogonal validation for a role of mutant Gnas R201C activation in regulating YAP1 activation through cytoplasmic sequestration was borne out by immunohistochemical staining for YAP1 expression in Kras;Gnas mice, with or without doxycycline ( Figure 5A) . In contrast to the strong nuclear localization of YAP1 protein in pancreatic precursor lesions (mPanINs) of all histological grades in mice without doxycycline administration (left), cytoplasmic localization was the predominant pattern seen in Kras;Gnas mice receiving doxycycline (right). This suggests that the impact of Gnas R201C activation on the Hippo pathway is an early event,
occurring at the step of pre-invasive neoplasia.
As the most profound impact of Gnas
R201C
-dependent YAP1 inactivation appears to be on the differentiation status of tumors, we assessed whether sustained YAP1 activity would "rescue" this phenotype. In paired allograft experiments, where we stably expressed either wild type YAP1, or the phosphorylation resistant YAP1 S127A mutant allele in LGKC-1 cells, the differentiation phenotype observed with doxycycline induction was completely abrogated when YAP1 S127A was expressed in LGKC-1 allografts ( Figure 5B ). To further explore the mechanistic basis of this striking epithelial differentiation phenotype, we examined the dynamics of α -Ecatenin localization in LGKC cells, derivative allografts and in the autochthonous models, with and without induction of Gnas R201C expression. In the epidermis, membranous localization of α -E-catenin has been implicated as a mediator of epidermal differentiation, wherein it also plays a role as a tumor suppressor through sequestering YAP1 in the cytoplasm 23 . Under sub-confluent conditions, addition of doxycycline to LGKC-1 cells was associated with strong membranous expression of α -E-catenin that coincided with cytoplasmic YAP1 sequestration ( Figure 6A ).
Moreover, in subcutaneous allografts generated from LGKC-1 cells, the previously described epithelial differentiation phenotype was also similarly associated with membranous α -E-catenin localization and nuclear YAP1 exclusion (Supplementary Figure 4A) ; this differential compartmentalization was also phenocopied in the autochthonous model. Specifically, while mPanIN lesions in Kras;Gnas mice with or without doxycycline induction expressed strong α -Ecatenin membrane localization, this pattern was lost in the setting of mutant Kras G12D induced invasive cancers, while retained in the differentiated PDAC that arose in the setting of concomitant Gnas R201C expression ( Figure 6B ).
YAP1 localization in human IPMNs in relationship to mutant GNAS status
In light of the impact of GNAS mutation on YAP1 localization in murine tissues, we performed [25] [26] [27] , respectively, in comparison to mice with pancreas-specific Kras G12D mutation alone 28 . On the contrary, in the Kras;Gnas mice, we did not observe the stated acceleration, with a median time to invasive carcinoma of 46 weeks (38 weeks post doxycycline) comparable to control mice, suggesting that Gnas R201C is not functioning as a traditional cooperating oncogene, but rather, as an "onco-modulator" that alters the phenotype of pre-invasive lesions arising in the context of mutant Kras G12D, and leads to invasive carcinomas with a predominantly well differentiated morphology. Expression profiling studies identified repression of the transcriptional co-activator YAP1 as a signature of Gnas R201C co-expression on the backdrop of mutant Kras G12D , through activation of the upstream inhibitory Hippo kinase cascade. Notably, YAP1 is inactivated through phosphorylation-dependent cytoplasmic sequestration, which we observed not only in murine autochthonous or allograft models upon induction of Gαs, but also in patient-derived IPMNs specimens with known GNAS mutations.
We were able to demonstrate the primacy of YAP1 sequestration in the Gαs-induced differentiation phenomenon, and the role of Hippo-induced phosphorylation as the mediator of this effect, through "rescue" experiments performed with a phosphorylation resistant mutant allele that completely reversed the differentiation effect in vivo.
YAP1 has been implicated as a critical transcriptional co-activator in both development and neoplasia, including that of the pancreas. We, and others, have previously demonstrated the transforming capabilities of YAP1 as an oncogene in the pancreatic epithelium 29, 30 ; specifically, YAP1 has been demonstrated to exhibit both cancer cell intrinsic growth properties (through induction of JAK-STAT3 and MYC signaling, amongst others) 31, 32 , as well as a profound impact on the tumor microenvironment by creating a permissive immune milieu 33 . Conversely, genetic ablation of YAP1 in the murine pancreas on a mutant Kras or Kras;p53 background blocks progression to PDAC, although the earliest precursor lesions (acinar ductal metaplasia)
are not impeded 34 . Notably, despite the abrogation of YAP1 signaling in our model, we do encounter eventual progression in a subset of mice to invasive cancers, suggesting that constitutive cAMP activation likely has additional downstream effects that sustain the neoplastic phenotype. Another key difference from the prior study pertains to embryonic ablation of YAP1 34 , which likely has more profound impact on the pool of pancreatic progenitors amenable to neoplastic transformation 35 , than Gαs-induced inhibition of YAP1 in the adult pancreas.
Irrespective, we believe that the inhibition of YAP1 signaling plays a profound role in attenuating the unchecked progression of IPMNs to PDAC, and could explain the favorable biology of these cystic neoplasms. This recalcitrance to invasive neoplasia might also explain why GNAS mutations are uncommon in PanIN lesions, which are the more common precursor to "conventional" adenocarcinoma and harbor a distinct natural history compared to IPMN-induced cancers.
While phosphorylation of YAP1 through the Hippo kinase cascade results in cytoplasmic sequestration, there is a strong selection pressure during carcinogenesis to unleash this important oncogenic signal through phosphatase-dependent de-phosphorylation and nuclear translocation.
Prior studies in epidermal keratinocytes and breast epithelium have shown the importance of the cell-cell adhesion protein α -E-catenin in "fencing in" phosphorylated YAP1 23, [36] [37] [38] , and shielding the phosphorylated protein from phosphatases like PP2A. Further, downregulation of α -E-catenin in cutaneous squamous cell carcinoma models was shown to result in poorly differentiated cancers with nuclear YAP1 translocation 23, 36 . In Kras;Gnas mice, we find that Gαs-induced YAP1 sequestration in the cytoplasm is accompanied by robust expression of membranous α -E-catenin, likely functioning as a cytoplasmic "restraint", while nuclear translocation of YAP1 (seen with mutant Kras G12D expression alone) is accompanied by loss of membrane expression of α -E-catenin. While some studies have suggested that α -E-catenin itself regulates the activity of YAP1 through a non-canonical Hippo-independent pathway 39 , we do not find definitive evidence to this effect in our model, since Gαs induction phosphorylates the canonical Hippo kinase LATS1, and at least in the precursor lesions arising in the setting of Kras G12D alone, we observe nuclear YAP1 expression despite robust membranous α -E-catenin localization (the latter, however, is lost in the invasive carcinomas).
In summary, we describe a murine model of IPMNs that recapitulates the genetic landscape of the most common drivers and the multistep progression observed in the cognate human cystic neoplasms. We identify the potential mechanistic basis for the relatively indolent biology of the cystic pathway to invasive neoplasia in the pancreas, and the role of constitutively active Gαs as an "onco-modulator" of epithelial differentiation in the context of mutant Kras. The Kras;Gnas model (and derivative reagents, such as isogenic cell lines) will be useful reagents for the community to pursue cross-species translational research endeavors in the context of early detection and cancer interception. (E) The cAMP elevator, forskolin, phenocopies the effects of Gαs induction on LATS1 and YAP1 S127/S397 phosphorylation. 
